PMID- 29138567
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 13
DP  - 2017
TI  - Resveratrol ameliorates chronic unpredictable mild stress-induced depression-like 
      behavior: involvement of the HPA axis, inflammatory markers, BDNF, and 
      Wnt/beta-catenin pathway in rats.
PG  - 2727-2736
LID - 10.2147/NDT.S150028 [doi]
AB  - Classic antidepressant drugs are modestly effective across the population and 
      most are associated with intolerable side effects. Recently, numerous lines of 
      evidence suggest that resveratrol (RES), a natural polyphenol, possesses 
      beneficial therapeutic activity for depression. The aim of the present study was 
      to explore whether RES exhibits an antidepressant-like effect in a depression 
      model and to explore the possible mechanism. A depression model was established 
      via chronic unpredictable mild stress (CUMS), after which the model rats in the 
      RES and fluoxetine groups received a daily injection of RES or fluoxetine, 
      respectively. The sucrose preference test, open field test, and forced swimming 
      test were used to explore the antidepressant-like effects of RES. The activity of 
      the hypothalamic-pituitary-adrenal (HPA) axis was evaluated by detecting the 
      plasma corticosterone concentration and hypothalamic mRNA expression of 
      corticotrophin-releasing hormone. The plasma interleukin-6 (IL-6), C-reactive 
      protein (CRP), and tumor necrosis factor-alpha (TNF-alpha) concentrations were measured 
      by enzyme-linked immunosorbent assay. Hippocampal protein expression of 
      brain-derived neurotrophic factor (BDNF) and the Wnt/beta-catenin pathway were 
      analyzed by western blot. The results showed that RES relieved depression-like 
      behavior of CUMS rats, as indicated by the increased sucrose preference and the 
      decreased immobile time. Rats that received RES treatment exhibited reduced 
      plasma corticosterone levels and corticotrophin-releasing hormone mRNA expression 
      in the hypothalamus, suggesting that the hyperactivity of the HPA axis in CUMS 
      rats was reversed by RES. Moreover, after RES treatment, the rats exhibited 
      increased plasma IL-6, CRP, and TNF-alpha concentrations. Furthermore, RES treatment 
      upregulated the hippocampal protein levels of BDNF and the relative ratio of 
      p-beta-catenin/beta-catenin while downregulating the relative ratio of p-GSK-3beta/GSK-3beta. 
      Our findings suggest that RES improved depressive behavior in CUMS rats by 
      downregulating HPA axis hyperactivity, increasing BDNF expression and plasma 
      IL-6, CRP, and TNF-alpha concentrations, and regulating the hippocampal Wnt/beta-catenin 
      pathway.
FAU - Yang, Xin-Hua
AU  - Yang XH
AD  - Department of Pharmacy, Hefei Eighth People's Hospital, Hefei.
FAU - Song, Su-Qi
AU  - Song SQ
AD  - Department of Psychiatry, Chaohu Hospital of Anhui Medical University, Hefei.
FAU - Xu, Yun
AU  - Xu Y
AD  - Faculty of Pharmacy, Anhui Medical University, Hefei, China.
LA  - eng
PT  - Journal Article
DEP - 20171027
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC5667793
OTO - NOTNLM
OT  - C-reactive protein
OT  - Wnt/beta-catenin pathway
OT  - brain-derived neurotrophic factor
OT  - chronic unpredictable mild stress
OT  - depression
OT  - hypothalamus-pituitary-adrenal axis
OT  - interleukin-6
OT  - resveratrol
OT  - tumor necrosis factor-alpha
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2017/11/16 06:00
MHDA- 2017/11/16 06:01
PMCR- 2017/10/27
CRDT- 2017/11/16 06:00
PHST- 2017/11/16 06:00 [entrez]
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2017/11/16 06:01 [medline]
PHST- 2017/10/27 00:00 [pmc-release]
AID - ndt-13-2727 [pii]
AID - 10.2147/NDT.S150028 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2017 Oct 27;13:2727-2736. doi: 10.2147/NDT.S150028. 
      eCollection 2017.